News brief­ing: Ax­o­vant re­ports im­proved mo­tor func­tion in small Parkin­son's tri­al; Bain life sci­ences SPAC files for $125M IPO

Ax­o­vant re­port­ed a snap­shot of Phase II fol­low-up da­ta from one co­hort in a small Parkin­son’s dis­ease tri­al Tues­day.

The treat­ment, a gene ther­a­py de­signed to sta­bi­lize dopamine lev­els in the brain, was well-tol­er­at­ed with all 4 pa­tients re­port­ing no se­ri­ous ad­verse ef­fects. On­ly two of the pa­tients proved to be evalu­able, but they re­port­ed an av­er­age of 40% im­prove­ment in cer­tain mo­tor func­tion. Ax­o­vant not­ed that the oth­er two pa­tients were not able to be eval­u­at­ed in this area due to one Covid-19-re­lat­ed is­sue and a re­fusal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER